Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Kenneth Allen Myszkowski. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Kenneth Allen Myszkowski har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ARWR / Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | 455 433 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Kenneth Allen Myszkowski. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Kenneth Allen Myszkowski som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −10 000 | 455 433 | −2,15 | 19,69 | −196 900 | 8 967 476 | |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 000 | 465 433 | −1,69 | 19,70 | −157 600 | 9 169 030 |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 402 | 473 433 | −1,95 | 20,10 | −188 980 | 9 516 003 |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −17 765 | 482 835 | −3,55 | 19,68 | −349 615 | 9 502 193 |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 100 000 | 500 600 | 24,96 | ||||
2024-03-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −40 000 | 400 600 | −9,08 | 35,19 | −1 407 600 | 14 097 114 | |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 904 | 440 600 | −1,98 | 35,65 | −317 428 | 15 707 390 |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 800 | 449 504 | −1,27 | 34,97 | −202 826 | 15 719 155 |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 400 | 455 304 | −0,31 | 34,04 | −47 656 | 15 498 548 |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 75 000 | 456 704 | 19,65 | ||||
2023-06-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −15 000 | 381 704 | −3,78 | 36,20 | −543 000 | 13 817 685 | |
2023-01-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 60 000 | 396 704 | 17,82 | ||||
2022-12-30 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −30 625 | 336 704 | −8,34 | 40,00 | −1 225 000 | 13 468 160 |
2022-09-30 |
|
5 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −96 676 | 367 329 | −20,84 | ||||
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 786 | 464 005 | −0,81 | 63,95 | −242 115 | 29 673 120 |
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 778 | 467 791 | −0,80 | 63,17 | −238 656 | 29 550 357 |
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 528 | 471 569 | −3,39 | 62,00 | −1 024 736 | 29 237 278 |
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −15 908 | 488 097 | −3,16 | 60,50 | −962 434 | 29 529 868 |
2022-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 60 000 | 504 005 | 13,51 | ||||
2021-01-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 441 | 444 005 | −0,32 | 81,00 | −116 721 | 35 964 405 | |
2021-01-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −11 597 | 445 446 | −2,54 | 81,02 | −939 589 | 36 090 035 | |
2021-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 166 | 457 043 | −5,22 | 72,63 | −1 827 807 | 33 195 033 |
2021-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 359 | 482 209 | −0,90 | 71,77 | −312 845 | 34 608 140 |
2021-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 100 | 486 568 | −0,23 | 70,75 | −77 825 | 34 424 686 |
2021-01-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 60 000 | 487 668 | 14,03 | ||||
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −43 505 | 0 | −100,00 | ||||
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −17 665 | 427 668 | −3,97 | 69,86 | −1 234 077 | 29 876 886 | |
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −25 840 | 445 333 | −5,48 | 69,04 | −1 783 994 | 30 745 790 | |
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 43 505 | 471 173 | 10,17 | 14,54 | 632 563 | 6 850 855 | |
2020-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −29 166 | 43 505 | −40,13 | ||||
2020-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −29 166 | 427 668 | −6,38 | 54,04 | −1 576 131 | 23 111 179 | |
2020-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 29 166 | 456 834 | 6,82 | 6,15 | 179 371 | 2 809 529 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −10 834 | 72 671 | −12,97 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 116 | 83 505 | −12,67 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 495 | 95 621 | −6,36 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −2 000 | 102 116 | −1,92 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 000 | 104 116 | −10,33 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10 834 | 427 668 | 2,60 | 6,15 | 66 629 | 2 630 158 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 116 | 416 834 | 2,99 | 7,75 | 93 899 | 3 230 464 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 495 | 404 718 | 1,63 | 14,54 | 94 437 | 5 884 600 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 000 | 398 223 | 0,50 | 5,19 | 10 380 | 2 066 777 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 000 | 396 223 | 3,12 | 9,90 | 118 800 | 3 922 608 | |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −33 351 | 116 116 | −22,31 | ||||
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 450 | 384 223 | −0,89 | 52,13 | −179 848 | 20 029 545 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 680 | 387 673 | −2,68 | 51,11 | −545 855 | 19 813 967 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 800 | 398 353 | −0,70 | 49,98 | −139 944 | 19 909 683 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 554 | 401 153 | −2,56 | 49,07 | −517 885 | 19 684 578 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 432 | 411 707 | −1,54 | 47,93 | −308 286 | 19 733 117 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 397 | 418 139 | −1,51 | 47,07 | −301 107 | 19 681 803 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 33 351 | 424 536 | 8,53 | 5,19 | 173 092 | 2 203 342 | |
2020-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −500 | 391 185 | −0,13 | 60,95 | −30 475 | 23 842 726 |
2020-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 907 | 391 685 | −2,95 | 60,40 | −719 183 | 23 657 774 |
2020-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 593 | 403 592 | −1,85 | 59,60 | −452 543 | 24 054 083 |
2020-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 85 000 | 411 185 | 26,06 | ||||
2019-11-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 649 | 149 467 | −7,80 | ||||
2019-11-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 649 | 326 185 | 4,03 | 5,19 | 65 648 | 1 692 900 | |
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −37 884 | 162 116 | −18,94 | ||||
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 620 | 313 536 | −5,03 | 41,21 | −684 910 | 12 920 819 |
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −21 264 | 330 156 | −6,05 | 40,56 | −862 468 | 13 391 127 |
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 37 884 | 351 420 | 12,08 | 7,75 | 293 601 | 2 723 505 | |
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 200 000 | −9,09 | ||||
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −15 000 | 220 000 | −6,38 | ||||
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 313 536 | 6,81 | 5,19 | 103 800 | 1 627 252 | |
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 15 000 | 293 536 | 5,39 | 4,60 | 69 000 | 1 350 266 | |
2019-05-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −27 071 | 278 536 | −8,86 | 22,00 | −595 562 | 6 127 792 |
2019-02-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −8 000 | 235 000 | −3,29 | ||||
2019-02-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 000 | 305 607 | −2,55 | 18,00 | −144 000 | 5 500 926 |
2019-02-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 8 000 | 313 607 | 2,62 | 5,20 | 41 600 | 1 630 756 | |
2019-01-18 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −81 875 | 305 607 | −21,13 | 14,55 | −1 191 281 | 4 446 582 |
2019-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −8 333 | 387 482 | −2,11 | 11,98 | −99 829 | 4 642 034 | |
2019-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 85 000 | 395 815 | 27,35 | ||||
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 243 000 | −7,60 | ||||
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −25 000 | 263 000 | −8,68 | ||||
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 000 | 310 815 | −6,05 | 21,01 | −420 200 | 6 530 223 |
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 000 | 330 815 | −7,03 | 18,00 | −450 000 | 5 954 670 |
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 355 815 | 5,96 | 4,75 | 95 000 | 1 690 121 | |
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 25 000 | 335 815 | 8,04 | 2,62 | 65 500 | 879 835 | |
2018-06-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 288 000 | −6,49 | ||||
2018-06-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 000 | 310 815 | −6,05 | 14,01 | −280 200 | 4 354 518 |
2018-06-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 330 815 | 6,43 | 2,01 | 40 200 | 664 938 | |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 600 | 308 000 | −3,93 | ||||
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 600 | 310 815 | −3,90 | 11,00 | −138 600 | 3 418 965 |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 600 | 323 415 | 4,05 | 2,01 | 25 326 | 650 064 | |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 400 | 320 600 | −0,43 | ||||
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 400 | 310 815 | −0,45 | 11,00 | −15 400 | 3 418 965 |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 400 | 312 215 | 0,45 | 2,01 | 2 814 | 627 552 | |
2018-03-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 322 000 | −5,85 | ||||
2018-03-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 000 | 310 815 | −6,05 | 8,00 | −160 000 | 2 486 520 |
2018-03-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 330 815 | 6,43 | 2,01 | 40 200 | 664 938 | |
2018-03-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −8 208 | 310 815 | −2,57 | 6,66 | −54 665 | 2 070 028 | |
2018-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 75 000 | 319 023 | 30,73 | ||||
2017-10-06 |
|
5 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −16 666 | 244 023 | −6,39 | ||||
2017-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 145 000 | 260 689 | 125,34 | ||||
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 900 | 342 000 | −1,98 | ||||
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 900 | 115 689 | −5,63 | 8,00 | −55 200 | 925 512 |
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 900 | 122 589 | 5,96 | 2,01 | 13 869 | 246 404 | |
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −13 100 | 348 900 | −3,62 | ||||
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 100 | 115 689 | −10,17 | 8,00 | −104 800 | 925 512 |
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 13 100 | 128 789 | 11,32 | 2,01 | 26 331 | 258 866 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 900 | 342 000 | −1,98 | ||||
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 900 | 115 689 | −5,63 | 8,00 | −55 200 | 925 512 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 900 | 122 589 | 5,96 | 2,01 | 13 869 | 246 404 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −13 100 | 348 900 | −3,62 | ||||
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −13 100 | 115 689 | −10,17 | 8,00 | −104 800 | 925 512 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 13 100 | 128 789 | 11,32 | 2,01 | 26 331 | 258 866 | |
2016-03-08 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −6 263 | 115 689 | −5,14 | 4,33 | −27 119 | 500 933 | |
2016-02-09 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −13 048 | 121 952 | −9,67 | 3,46 | −45 146 | 421 954 | |
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 40 000 | 362 000 | 12,42 | ||||
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 50 000 | 135 000 | 58,82 | ||||
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
S - Sale | −23 347 | 85 000 | −21,55 | 6,13 | −143 117 | 521 050 | |
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −13 153 | 108 347 | −10,83 | 6,13 | −80 628 | 664 167 | |
2015-03-06 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 50 000 | 322 000 | 18,38 | ||||
2015-03-06 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 50 000 | 121 500 | 69,93 | ||||
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option (right to buy) |
M - Exercise | −25 000 | 272 000 | −8,42 | ||||
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option (right to buy) |
M - Exercise | −15 000 | 297 000 | −4,81 | ||||
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
S - Sale | −40 000 | 71 500 | −35,87 | 14,02 | −560 860 | 1 002 537 | |
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
M - Exercise | 25 000 | 111 500 | 28,90 | 7,00 | 175 000 | 780 500 | |
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
M - Exercise | 15 000 | 86 500 | 20,98 | 5,19 | 77 850 | 448 935 | |
2014-02-12 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
M - Exercise | −16 000 | 312 000 | −4,88 | ||||
2014-02-12 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
S - Sale | −16 000 | 71 500 | −18,29 | 18,77 | −300 290 | 1 341 919 | |
2014-02-12 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
M - Exercise | 16 000 | 87 500 | 22,38 | 2,01 | 32 160 | 175 875 | |
2014-02-10 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Options |
A - Award | 50 000 | 328 000 | 17,99 | ||||
2014-02-10 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 70 000 | 71 500 | 4 666,67 | ||||
2013-09-24 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 20 000 | 278 000 | 7,75 | ||||
2013-05-08 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 90 000 | 258 000 | 53,57 | ||||
2012-10-02 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 25 000 | 168 000 | 17,48 | ||||
2012-02-21 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 83 000 | 143 000 | 138,33 |